| Title | Severe obstructive sleep apnea after cerivastatin therapy: a case report. | | Author(s) | Ebben MR, Sethi NK, Spielman AJ | | Institution | Center for Sleep Medicine, Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 525 East, 68th Street, New York, NY 10021, USA. mae2001@med.cornell.edu | | Source | J Clin Sleep Med 2008 Jun 15; 4(3):255-6. | | Abstract | All available 3-hydroxy-3-methyglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have been implicated in causing rhabdomyolysis either as monotherapy or in combination with other myotoxic drugs such as cyclosporine, colchicine and fibrates. Cerivastatin (Baycol) is a third generation statin, which has been implicated in cases of fatal rhabdomyolysis. It was voluntary withdrawn from the U.S. market by Bayer after reports of fatal rhabdomyolysis appeared in the literature. We present here a case of an 85-year-old woman who developed rhabdomyolysis and severe obstructive sleep apnea (OSA) symptoms after having been started on cerivastatin therapy for hypercholesteremia. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 18595439 |
|
